AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease

AbbVie (ABBV) Shares Fall 6% Following Revenue Miss

July 29, 2022 12:04 PM EDT

AbbVie (NYSE: ABBV) shares tumbled 6% Friday following its earnings report before the open, which beat earnings estimates but missed revenue expectations.

The biopharmaceutical company posted earnings per share of $3.37, $0.03 above expectations of $3.34, with revenue missing the consensus estimate of $14.67 billion, coming in at $14.58 billion. However, revenue did increase 4.5%... More